Lexaria Bioscience (LEXX) said Wednesday it received the independent ethics board approval to initiate a human pilot study to compare an oral version of liraglutide with the conventional injected method.
The company said the oral version is formulated using DehydraTECH-processing and the pilot study will focus on safety and pharmacokinetic performance in humans.
Novo Nordisk markets liraglutide's injectable form as Saxenda and Victoza for weight loss and treatment of diabetes.
Shares of Lexaria were up over 6% in recent trading.
Price: 2.06, Change: +0.13, Percent Change: +6.94
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。